TY - JOUR T1 - Clark, et al, reply JF - The Journal of Rheumatology JO - J Rheumatol SP - 203 LP - 203 DO - 10.3899/jrheum.090404 VL - 37 IS - 1 AU - CHRISTINE A. CLARK AU - KAREN A. SPITZER AU - CARL A. LASKIN Y1 - 2010/01/01 UR - http://www.jrheum.org/content/37/1/203.abstract N2 - To the Editor:We read with interest Dr. Carp’s comments regarding the HepASA trial. The questions he raises about our inclusion criteria and conclusions are those that have surrounded therapeutic trials for recurrent pregnancy loss (RPL) with or without antiphospholipid antibodies (aPL) for decades.Dr. Carp suggests that stratification for this patient population should include age and number of previous losses. The issue of evaluating and treating women with a history of 2 versus 3 losses continues to be debated, and evidence supporting both contentions is available and used by investigators according to their convictions. As noted, we and others have observed that causes of RPL are similar in women with 2 or 3 losses1,2. Brigham, et al, in a longitudinal study of 325 patients with idiopathic RPL, found that women with a history of 2 versus 3 previous losses had the same chances of success in a subsequent pregnancy (76% vs 79%)3. Intuitively, therefore, if, in … Address correspondence to C. Clark; E-mail: cclarksolo{at}aol.com ER -